The Life Sciences team advised Orca Bio on the completion of a Series F financing round in December 2025 led by Lightspeed Venture Partners. With $250 million in new equity capital from its two most recent financing rounds, along with a 2025 amendment to its Silicon Valley Bank credit facility providing up to $100 million in additional liquidity, Orca Bio possesses the financial strength to scale its commercial operations and advance its clinical pipeline.
Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company's manufacturing platform uses single-cell precision to create personalized cell therapy products intended to replace a patient's diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what's possible for patients by transforming the field of curative allogeneic cell therapy.
The Goodwin team was led by Kevin Kabler and Zach Newman.
For more information on the deal, please read the press release.